1. Scrip
  2. >>Business
  3. >>Strategy

Investors Hit The Alarm Bells As Indivior Issues Profit Warning

 
• By Kevin Grogan

The UK group remains confident that the scale of the US opioid epidemic, driven by misuse of fentanyl, still represents a considerable opportunity but investors have reacted nervously to lower revenues coming from Sublocade.

Mark Crossley
CEO Mark Crossley • Source: Indivior

Investors have not reacted well to Indivior plc's business update and bad news on earnings plus a schizophrenia drug that is no longer commercially viable have sent the UK firm's share price to the floor.

Indivior, which switched its primary listing to the US last month but still trades on the FTSE 250 in London, said that adjusted operating profits would be in the range of $285m-$320m for the year, down from a forecast issued only a couple of weeks ago of $330m-$380m. Revenue for full-year 2024 is expected to be around $1.15bn-$1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.